You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金丨開源證券:恩華藥業業績驅動因素明確,維持“買入”評級
格隆匯 07-31 15:34
開源證券研報指出,恩華藥業神經類業務快速增長,業績驅動因素明確,維持“買入”評級。公司深化挖掘產品差異化優勢,實現成熟產品力月西、福爾利、瑞芬太尼等穩定成長,加快創新產品TRV130、羥考酮注射液、舒芬太尼、阿芬太尼及BD合作新產品安泰坦®的市場開拓。公司不斷加大研發投入,目前共有17項在研創新藥項目,其中完成Ⅲ期臨牀研究項目1項(NH600001乳狀注射液);完成Ⅱ期臨牀研究項目2項(NHL35700片、YH1910-Z02注射液);開展Ⅱ期臨牀研究項目2項(NH102片、YH1910-Z01鼻噴劑);開展I期臨牀研究項目6項(NH130片、NH104片、Protollin鼻噴劑、NH160030片、NH140068片、NH280105膠囊);獲得臨牀試驗通知書項目1項(枸櫞酸舒芬太尼注射液(新增適應症));其餘項目均處於臨牀前研究階段,市場潛力較大。公司業績驅動因素明確,創新研發穩步推進。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account